South American health authorities said Brazil has suspended clinical trials of its Bharat Biotech Covaxin COVID-19 vaccine following the expiration of its company agreement with its partner.
Bharat Biotech announced the termination of contracts with Precisa Medicamentos and Envixia Pharmaceuticals LL.C. Friday 23 July 2021 Letter of intent signed for the Covaxin COVID-19 vaccine for the Brazilian market.
The agreement was terminated after an agreement was reached with the Brazilian government to supply 20 million doses of the vaccine, which contradicted and prompted an investigation by national authorities.
Anvisa Clinical Trials Coordination (Copec / GGMED) decided this Friday (23/7) to discontinue clinical trials of the Covaxin vaccine in Brazil as a precautionary measure. Brazilian health authority Anvisa has announced the suspension based on a statement from the Indian company Bharat Biotech Limited International posted by Anvisa on Friday (23 July).
Precisa Medicamentos partnered with Bharat Biotechs in Brazil, providing regulatory proposals, licensing, distribution, insurance and support, advice and assistance for Phase lll clinical trials.
Srinagar: due to the result of the Post-Civilian killings and in the days running up regarding the visit of Union Minister Amit Shah in Srinagar durin...
Mumbai: NCB officer was asked whether he would take any legal action against the NCP leader Nawab Malik. And the allegations that were made by him, th...